Engineered donor cells aim to beat blood cancer without Graft-Versus-Host disease
NCT ID NCT03849651
First seen Mar 14, 2026 · Last updated Apr 28, 2026 · Updated 5 times
Summary
This study tests a new way to do stem cell transplants for children and young adults with high-risk blood cancers like leukemia and lymphoma. Donor cells are treated in a lab to remove certain T cells that can cause a serious side effect called graft-versus-host disease. After the transplant, patients also get an extra infusion of memory T cells to help fight the cancer. The goal is to see if this approach is safe and improves survival without relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Conditions
Explore the condition pages connected to this study.